← Leaderboards
Xiaoliu Zhang
Baylor College Of Medicine
$8,408,799
Attributed
$8,408,799
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $690.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,408,799 · 5
By mechanism
R01$8,408,799 · 5
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Traber L Giardina$1,755,494
- John M Hollier$1,287,126
- Florante A Quiocho$4,334,936
- Geoffrey A Preidis$3,637,590
- Hyuntaek Oh$864,881
Others in their field
Top investigators on “Oncolytic Viruses”
- David Heimbrook · Leidos Biomedical Research, Inc.$87,846,116
- Larry Arthur$33,360,682
- Arzu Onar-Thomas · St. Jude Children'S Research Hospital$17,206,154
- Balveen Kaur · Ohio State University$17,190,426
- E. Antonio Chiocca · Massachusetts General Hospital$16,781,017
- Ira J Dunkel · St. Jude Children'S Research Hospital$15,842,881
Research focus
Oncolytic VirusesIn VivoOncolyticNeoplastic CellSimplexvirusTumorVirusDesignTranslatingBaseMalignant NeoplasmsClinical TrialsFutureHuman Herpesvirus 2Cell KillingClinical ApplicationPropertyTreatment EfficacyRouteIn VitroImmunityMediatingSuccessKillings
Grant awards (31)
Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunity$384,242
R01 · FY2025 · CA · contact PI
Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunity$365,032
R01 · FY2024 · CA · contact PI
Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunity$376,557
R01 · FY2023 · CA · contact PI
Actively engaging NK cells during virotherapy to induce neoantigen-specific antitumor immunity$384,242
R01 · FY2022 · CA · contact PI
Reconstruction of an oncolytic HSV vector for systemic delivery$346,308
R01 · FY2020 · CA · contact PI
Reconstruction of an oncolytic HSV vector for systemic delivery$335,988
R01 · FY2019 · CA · contact PI
Novel Strategies to Potentiate a Ras-targeted Oncolytic Herpes Simplex Virus$333,702
R01 · FY2019 · CA · contact PI
Reconstruction of an oncolytic HSV vector for systemic delivery$346,450
R01 · FY2018 · CA · contact PI
Novel Strategies to Potentiate a Ras-targeted Oncolytic Herpes Simplex Virus$344,023
R01 · FY2018 · CA · contact PI
Reconstruction of an oncolytic HSV vector for systemic delivery$344,205
R01 · FY2017 · CA · contact PI
Novel Strategies to Potentiate a Ras-targeted Oncolytic Herpes Simplex Virus$344,023
R01 · FY2017 · CA · contact PI
Novel Strategies to Potentiate a Ras-targeted Oncolytic Herpes Simplex Virus$349,308
R01 · FY2016 · CA · contact PI
Reconstruction of an oncolytic HSV vector for systemic delivery$341,029
R01 · FY2016 · CA · contact PI
Novel Strategies to Potentiate a Ras-targeted Oncolytic Herpes Simplex Virus$351,363
R01 · FY2015 · CA · contact PI
Development of an HSV-2 based oncolytic virus$283,799
R01 · FY2013 · CA · contact PI
Development of an HSV-2 based oncolytic virus$53,244
R01 · FY2013 · CA · contact PI
Development of an HSV-2 based oncolytic virus$301,913
R01 · FY2012 · CA · contact PI
Strategies to Enhance Virotherapy for Breast Cancer$218,246
R01 · FY2012 · CA · contact PI
Development of an HSV-2 based oncolytic virus$22,845
R01 · FY2012 · CA · contact PI
Development of an HSV-2 based oncolytic virus$301,913
R01 · FY2011 · CA · contact PI
Strategies to Enhance Virotherapy for Breast Cancer$218,246
R01 · FY2011 · CA · contact PI
Development of an HSV-2 based oncolytic virus$311,250
R01 · FY2010 · CA · contact PI
Strategies to Enhance Virotherapy for Breast Cancer$224,996
R01 · FY2010 · CA · contact PI
Development of an HSV-2 based oncolytic virus$202,620
R01 · FY2009 · CA · contact PI
Strategies to Enhance Virotherapy for Breast Cancer$194,488
R01 · FY2009 · CA · contact PI
Development of an HSV-2 based oncolytic virus$113,250
R01 · FY2009 · CA · contact PI
Strategies to Enhance Virotherapy for Breast Cancer$46,827
R01 · FY2009 · CA · contact PI
STRATEGIES TO ENHANCE VIROTHERAPY FOR BREAST CANCER$234,030
R01 · FY2007 · CA · contact PI
STRATEGIES TO ENHANCE VIROTHERAPY FOR BREAST CANCER$241,020
R01 · FY2006 · CA · contact PI
STRATEGIES TO ENHANCE VIROTHERAPY FOR BREAST CANCER$246,820
R01 · FY2005 · CA
STRATEGIES TO ENHANCE VIROTHERAPY FOR BREAST CANCER$246,820
R01 · FY2004 · CA